Our results show that reducing the activity of ACC1-mediated de novo FAS can restrict colonic tumor initiation in vivo, which is in line with previous results of ACC1 inhibition in a colon cancer cell line and a report suggesting a specific effect of FAS inhibition on cancer stem cells42,43. The gene discussed is FAS; the disease is cancer.